The stakes of the question are hard to overstate. Suicide claims hundreds of thousands of lives worldwide each year, ranks as the second leading cause of death among young people, and places a heavy burden on families and health systems. Suicidal ideation — thoughts of self-harm or the feeling that death would be preferable — is among the strongest predictors of eventual suicidal behavior, which makes its early detection a central goal of prevention science. The World Health Organization has set an ambitious target of reducing suicide mortality by one-third by 2030, but the most established risk factors, from sociodemographic hardship to major depressive disorder, are notoriously difficult to modify or to catch in time to act. That gap has pushed researchers toward biological markers: measurable, potentially modifiable, and ideally detectable in a routine blood draw. Lipids have long been recurring candidates, with decades of studies asking whether low cholesterol raises suicide risk — and yielding results that never quite replicated.

ApoB is, at first glance, an unlikely suspect for a psychiatric investigation. It is the core structural protein of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles, the lipid-carrying packages implicated in atherosclerosis and heart disease. Because every one of these particles carries exactly one ApoB molecule, measuring ApoB effectively counts the total number of cholesterol- and triglyceride-transporting particles in the blood — a metric many cardiologists consider a more faithful gauge of atherosclerotic cardiovascular risk than LDL cholesterol concentration alone. Synthesized mainly by the liver and small intestine, ApoB’s day job is delivering lipids to peripheral tissues. But in recent years it has begun surfacing in psychiatric literature as well: serum ApoB has been linked to depression and to the cognitive deficits observed in depressed patients, and lipid metabolism is increasingly recognized as a genuine player in brain function, with the potential to influence neuroinflammation, oxidative stress, and the stability of the blood-brain barrier. Earlier studies on ApoB and suicidality, however, had pointed in conflicting directions, some implicating low ApoB levels and others finding no link at all.

To probe the question systematically, a team in China led by corresponding authors Huqiang Dong of Ningxia Medical University and Hongping Cheng of Hubei University of Medicine mined the National Health and Nutrition Examination Survey (NHANES), a nationally representative, biennial assessment of the health and nutritional status of the U.S. population. From 29,902 individuals enrolled in the 2011–2016 cycles, the researchers excluded anyone younger than 20, anyone lacking suicidal-ideation or ApoB measurements, and anyone with incomplete covariate data, leaving 6,520 adults with a mean age of 49.7 years, split almost evenly between men and women. ApoB concentrations were measured in venous blood samples with standardized immunoassays — a turbidimetric assay on a Roche Cobas 6000 analyzer in the 2015–2016 cycle and a nephelometric assay on a Siemens ProSpec analyzer in 2013–2014 — with a lower limit of detection of 25.0 mg/dL and strict quality-control procedures. Suicidal ideation was captured by item nine of the Patient Health Questionnaire-9 (PHQ-9), which asks whether, in the past two weeks, respondents have “often had thoughts of self-harm or thought that death would be better.” Any answer other than “not at all” was counted as suicidal ideation.

The statistical picture that emerged was strikingly consistent. Treating ApoB as a continuous variable, the team built three logistic regression models of increasing adjustment, and the positive association with suicidal ideation survived all of them, holding at P = 0.0463 in the fully adjusted model. Split into tertiles, participants in the middle ApoB group had 56 percent higher odds of suicidal ideation than those in the lowest group (odds ratio 1.56, 95% confidence interval 1.11–2.21, P = 0.0112), while those in the highest tertile showed roughly 48 percent higher odds (odds ratio 1.48, 95% confidence interval 1.04–2.12, P = 0.0312). A trend test across tertiles was significant in every model. To test for non-linearity, the researchers fitted a generalized additive model with a smooth term for ApoB; the fit was significant (P = 0.0109), but the effective degrees of freedom of the smooth term hovered near one — statistical evidence that the relationship was essentially linear: more ApoB, more risk, with no hidden threshold.

The most provocative result came from the subgroup analyses. Across strata of race, education, marital status, body mass index, hypertension, and diabetes, the ApoB–ideation association held steady, with no significant interactions. But when the sample was stratified by smoking status, the association sharpened markedly among smokers, and the interaction test returned P = 0.034 — statistical shorthand for evidence that smoking modifies the relationship. The authors advance two complementary explanations. Biologically, smoking drives chronic low-grade neuroinflammation, flooding the nervous system with inflammatory mediators that could amplify any pro-inflammatory effect of ApoB-rich lipoproteins in the brain and, over time, reshape the circuits that govern emotional regulation. Behaviorally, cigarettes are frequently used as a coping mechanism for negative emotions and stress, a pattern that entangles nicotine dependence with psychological distress and, epidemiologically, with suicidal tendencies. In smokers, the ApoB signal may simply be louder.

Correlation, however, is not causation, and observational studies of lipids are haunted by confounding and reverse causation — depression itself reshapes diet, metabolism, and lipid profiles. To probe causality, the team deployed Mendelian randomization, a technique that exploits the random shuffling of genes at conception as a natural experiment: genetic variants robustly associated with higher ApoB serve as proxies for lifelong exposure, and because they are inherited randomly and fixed before illness develops, they are largely immune to the confounding that plagues observational data. The researchers drew their instruments from a genome-wide association study (GWAS) of 233 blood metabolites conducted by Karjalainen and colleagues on up to 120,241 participants across 33 European cohorts, quantified with high-throughput nuclear magnetic resonance metabolomics. Outcome data came from the UK Biobank, where a GWAS of suicidal ideation in 365,819 participants of European descent was run with SAIGE, a generalized linear mixed model built to handle case-control imbalance. After stringent quality control — linkage-disequilibrium clumping at r² < 0.001, removal of rare variants, harmonization of effect alleles, and screening for pleiotropic outliers with Radial MR and MR-PRESSO — 116 single nucleotide polymorphisms survived as instruments, together explaining 11.33 percent of the variance in ApoB, with F-statistics ranging from 30.03 to 1040.20, far beyond the threshold for weak-instrument bias.

The verdict was null. The primary inverse-variance weighted analysis, which combines the per-variant Wald ratios into a single causal estimate, yielded an odds ratio of 1.24 (95% CI 0.90–1.71, P = 0.181) for the effect of ApoB on suicidal ideation. Four complementary methods converged: the generalized summary-data-based MR approach (GSMR), which additionally performs a HEIDI-outlier test, produced an odds ratio of 1.23 (P = 0.207); the robust adjusted profile score method (MR-RAPS), designed to tolerate pleiotropy and weak instruments, gave 1.22 (P = 0.238); the maximum likelihood method and the constrained maximum likelihood approach with model averaging and Bayesian information criterion (cML-MA-BIC) both returned 1.24. Sensitivity analyses were clean across the board: Cochran’s Q detected no heterogeneity, the MR-Egger intercept test and the MR-PRESSO global test found no horizontal pleiotropy, and leave-one-out analysis showed that no single variant dominated the pooled estimate. An MR Steiger test confirmed the instruments pointed in the correct causal direction, from ApoB toward suicidal ideation rather than the reverse.

Crucially, a post-hoc power analysis indicated that the MR study had 80 percent power to detect a causal odds ratio of 1.35 or larger, given the 116 instruments, the 11.33 percent of ApoB variance explained, and the 365,819-participant outcome GWAS — meaning the null result most likely reflects a genuine absence of strong causality rather than a study too underpowered to see the effect. That leaves the observational association demanding a biological story, and the authors sketch three. First, ApoB-laden lipoproteins are tied to neuroinflammation and oxidative stress, and ApoB itself has been shown to bind enolase-1 and aggravate inflammation; chronic low-grade inflammation is a well-replicated correlate of suicidal behavior. Second, hyperlipidemia is associated with increased permeability of the blood-brain barrier, raising the possibility that ApoB-associated particles entering the brain could provoke localized inflammatory responses and disrupt mood regulation. Third, lipoprotein metabolism intersects with cholesterol synthesis and utilization, which sustain synaptic membrane fluidity and receptor function — disturbances of which can destabilize neurotransmitter signaling.

The study’s limits are acknowledged candidly. The NHANES data are cross-sectional, so the association cannot establish temporal sequence; unmeasured confounders, or the metabolic fingerprints of mental illness itself, could still explain the pattern. The MR analysis, for all its rigor, cannot fully escape caveats about weak instruments, residual pleiotropy, and population stratification, and both the NHANES and GWAS samples derive from U.S. and European populations, constraining generalizability to other ancestries. Still, the work’s strengths — a nationally representative sample, triangulation across two fundamentally different methods, and exhaustive sensitivity testing — make it a substantive contribution. Its practical upshot is twofold: ApoB may deserve attention as a correlate worth tracking in suicide-risk research, particularly among smokers, and the biology linking lipid transport to suicidal thinking likely runs through indirect pathways — inflammation, barrier integrity, and cholesterol-dependent synaptic signaling — that genetic instruments for circulating ApoB alone cannot capture. Longitudinal and mechanistic studies, the authors conclude, must now determine whether ApoB is a genuine player in suicide risk or a metabolic bystander standing close to the fire.

Schizophrenia, a severe and long-lasting mental health disorder, presents with a complex array of symptoms including delusions, hallucinations, cognitive deficits, and mood disturbances. It has long been recognized that patients with chronic schizophrenia experience higher rates of suicide compared to the general population, but the pathways leading to suicidal thoughts are multifactorial and diverse. While previous studies have linked psychopathology and medication side effects to increased suicide risk, the new study asserts that biological inflammation markers also play an integral role. This paradigm shift towards viewing schizophrenia through a neuroimmune lens opens new vistas for both prediction and intervention.

Conducted between May and December 2018, the study examined 302 patients diagnosed with chronic schizophrenia. The research design was comprehensive: it included a thorough gathering of demographic data via self-administered questionnaires, combined with detailed psychopathological assessments using validated clinical scales. Specifically, the Calgary Depression Scale (CDSS) was employed for measuring depressive symptoms, while the Positive and Negative Syndrome Scale (PANSS) provided a granular evaluation of psychotic symptoms. Beyond psychological data, the study also measured plasma levels of key inflammatory cytokines—namely interleukin (IL)-1β, IL-6, IL-17A, and tumor necrosis factor-alpha (TNF-α). This integrated approach—melding psychiatric evaluation with immunological data—embodies a holistic understanding of schizophrenia’s biological complexities.

Notably, the researchers applied logarithmic transformations to cytokine levels to normalize the data for rigorous statistical analysis. These transformed variables served as independent predictors alongside psychopathological measures, with suicidal ideation as the dependent variable. Their analytical strategy included controlling for potential confounders such as age, body mass index (BMI), and years of education, ensuring robustness in their findings. Stepwise multifactorial logistic regression was used to isolate independent factors associated with suicidal ideation, complemented by receiver operating characteristic (ROC) curve analyses to evaluate the predictive power of these factors.

One of the most striking outcomes from the study was the high prevalence of lifetime suicidal ideation found among chronic schizophrenia patients, standing at an alarming 36.4%. Furthermore, 8.0% reported suicidal thoughts within the past week, underscoring ongoing acute risk. These figures starkly highlight the continuous threat of suicide in this population and the urgent need for effective risk stratification and management strategies in clinical settings.

After meticulous adjustment for demographic variables, the study revealed that female gender, elevated depressive symptoms measured by CDSS, and increased levels of IL-1β were independently associated with lifetime suicidal ideation. This suggests that beyond the recognized psychological aggravators, inflammatory processes may be intimately linked with longstanding suicidal risk. The cytokine IL-1β, a potent pro-inflammatory mediator, is known to influence brain function and behavior and might act through mechanisms such as neuroinflammation, oxidative stress, or neuroendocrine dysregulation to amplify vulnerability.

In contrast, suicidal ideation reported in the last week was independently linked to different factors: higher doses of antipsychotic medication (measured in chlorpromazine equivalents), more severe psychotic symptoms (via PANSS), increased depression severity (CDSS), and elevated IL-6 levels. The involvement of IL-6, another key cytokine implicated in systemic inflammation and neuroimmune communication, further reinforces the concept that current inflammatory status correlates with near-term suicidal risk. Medication side effects and acute psychopathology thus remain pivotal considerations alongside biochemical markers.

The ROC curve analyses underscored the combined utility of psychological and biological markers in predicting suicidal ideation. For lifetime SI, a model integrating depression scores and IL-1β levels demonstrated superior discriminative ability, while for recent SI, a four-factor model composed of antipsychotic dosage, psychotic symptoms, depressive symptoms, and IL-6 levels yielded improved predictive accuracy. These findings advocate for multidimensional suicide risk assessment frameworks that transcend symptom checklists to include immune system indicators.

Clinically, the implications of this study are profound. The elevated prevalence of SI and its associations with immune markers call for routine screening of depressive and psychotic symptom severity as well as consideration of inflammatory status within therapeutic protocols. It is conceivable that interventions targeting inflammation might emerge as adjunctive therapies for reducing suicidal risk in schizophrenia. Moreover, recognizing the roles of medication side effects and detailed symptomatology can further refine personalized treatment and monitoring plans.

This research also invites future exploration into the causative pathways linking cytokine dysregulation to suicidal ideation. Neuroinflammation may modulate neurotransmitter systems, brain circuitry, and stress responses, all pivotal in mood and behavior regulation. Clarifying whether these immune changes are causal or epiphenomenal will guide the development of targeted interventions. Longitudinal studies examining dynamic shifts in cytokine profiles alongside symptom trajectories are particularly warranted.

Furthermore, the study highlights the importance of addressing gender differences in schizophrenia-related suicide risk. Female patients showed a stronger association with lifetime SI, suggesting possible biological or psychosocial divergences that merit tailored preventative approaches. This finding challenges stereotypes and encourages gender-sensitive psychiatric care models.

In a broader context, the integration of psychopathology and immunology reflects a growing trend in psychiatric neuroscience recognizing mental illness as interconnected with peripheral systemic biology. This study exemplifies the value of interdisciplinary research melding psychiatry, immunology, and epidemiology. It positions inflammation as a nexus point that could revolutionize understanding and management of complex psychiatric conditions such as schizophrenia.

As the global burden of schizophrenia continues to grow alongside concerns about suicide in serious mental illness, studies like this provide hope for breakthroughs in early identification, prevention, and improved quality of life. The converging evidence that inflammation intricately participates in suicidal ideation opens novel therapeutic avenues—including anti-inflammatory drugs and lifestyle modifications aimed at regulating immune function.

In conclusion, the study published in BMC Psychiatry elucidates key relationships between suicidal ideation, psychopathology, medication effects, and inflammatory cytokines in chronic schizophrenia patients. By pioneering this combined approach, the authors equip clinicians and researchers with new tools and insights to tackle one of psychiatry’s most urgent challenges—mitigating suicide risk through a nuanced understanding of biological and psychological interplay. Innovative and integrative strategies born from such research hold promise to transform patient outcomes and save lives worldwide.

Subject of Research: The study investigates the associations of suicidal ideation with psychopathological symptoms and inflammatory cytokines in patients diagnosed with chronic schizophrenia.

Article Title: The associations of suicidal ideation with psychopathology and inflammatory cytokines in patients with chronic schizophrenia

Article References:
Liu, L., Zhao, L., Xiao, Z. et al. The associations of suicidal ideation with psychopathology and inflammatory cytokines in patients with chronic schizophrenia. BMC Psychiatry 25, 793 (2025). https://doi.org/10.1186/s12888-025-07263-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07263-8